HOME >> MEDICINE >> NEWS
International breast cancer prevention study launches in the United States and Canada

es national and international trials of cancer therapy, including trials for new cancer drugs, cancer prevention and supportive care to improve quality of life for people with cancer. Since its inception, the NCIC CTG has enrolled more than 40,000 patients from Canada and around the world in over 300 clinical trials.

Pfizer, Inc. manufactures exemestane under the brand name Aromasin and is providing the drug for the trial.

Women looking for more information about the ExCel research study and participating study centers in their community can visit www.excelstudy.com or call toll-free:

  • In the U.S. 1-800-4-CANCER
  • In Canada 1 888 939-3333

    About Exemestane

    Exemestane (Aromasin) was approved in the United States late in 1999 for the treatment of advanced breast cancer in postmenopausal women whose tumors have stopped responding to tamoxifen. Exemestane is approved by the FDA and Health Canada and is marketed by Pfizer, Inc. as Aromasin. It is also approved for use in Europe, Japan, and South America. It is currently used for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

    Results of the Intergroup Exemestane Study, published in the New England Journal of Medicine, revealed that 32 percent fewer women had a recurrence in their breast cancer when they switched to exemestane after two to three years of tamoxifen compared to those who continued on tamoxifen for a total of five years, the current standard of care. Additionally, twice as many women receiving tamoxifen developed second (or new) breast cancers than those treated with exemestane.

    Unlike other aromatase inhibitors, exemestane is a steroidal aromatase inactivator, which means it selectively targets and irreversibly binds to the aromatase enzyme, which is required to produce estrogen. Without estrogen, breast can
    '"/>



  • Contact: Samantha Kaplan
    samantha.kaplan@edelman.com
    312-297-7439
    Edelman Public Relations
    30-Mar-2005


    Page: 1 2 3 4

    Related medicine news :

    1. National Academies advisory: May 2 Symposium on International Science Policy
    2. Awards & fellowships at the International & American Association for Dental Research General Session
    3. Lectures, keynoters, symposia highlight International Dental Research meeting
    4. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
    5. International gathering of experts to share retinoblastoma breakthroughs
    6. International trial of two microbicides begins
    7. International gathering at UH examines top computer code
    8. International trial finds benefits of breast MRI in women at high risk
    9. International study provides culture-by-culture clues to family violence and abuse
    10. St. Jude scientist wins International Society of Experimental Hematology award
    11. International MRC trial finds a routine treatment for head injury may do more harm than good

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:7/22/2018)... ... 2018 , ... In an upcoming episode of “On Demand,” host Rob Lowe ... a type of medicine that considers the well-being the whole person when addressing an ... discipline that hones in on the curative relationship between the patient and medical profession, ...
    (Date:10/13/2017)... Milwaukee, WI (PRWEB) , ... October 13, 2017 , ... ... movement in medicine known as “patient engagement.” The patient is doing more than filling ... research partners. , “There is an increasing emphasis in health care and research ...
    (Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
    (Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
    Breaking Medicine News(10 mins):
    (Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
    (Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
    (Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
    Breaking Medicine Technology:
    Cached News: